Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Completed Phase 2 Interventional

Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea

NCT03189173
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Oral appliance, Oxygen, Oral appliance plus oxygen, No treatment
Device · Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 79 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

NCT00109083
View directory record Official record
Conditions
Migraine Headaches
Interventions
RWJ-333369
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
25
States / cities
Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 22, 2026, 2:33 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

NCT04311073
View directory record Official record
Conditions
Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions
Tranexamic Acid, Placebos
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Southeastern Collaboration to Improve Blood Pressure Control

NCT02866669
View directory record Official record
Conditions
Hypertension
Interventions
Practice Facilitation, Peer Coach, Enhanced usual care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
1,592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

NCT01054729
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir, Placebo, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 22, 2026, 2:33 PM EDT
Completed No phase listed Observational

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavior Therapy (CBT), Nonspecific Supportive Therapy (PBO)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

NCT02453256
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

NCT01458951
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
62
States / cities
Tucson, Arizona • Oceanside, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional

Obese Patients With or Without Comorbidities (RIO-North America)

NCT00029861
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 22, 2026, 2:33 PM EDT
Recruiting No phase listed Observational

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

NCT06259669
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
958 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

NCT00530166
View directory record Official record
Conditions
Asthma
Interventions
JNJ-18054478, sham comparator
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects and Mechanisms of Smartphone-Based Stress Management Training on Well-Being in College Students

NCT05518656
View directory record Official record
Conditions
Emotion Regulation
Interventions
Experimental intervention, Comparison intervention
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 25 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 22, 2026, 2:33 PM EDT
Completed No phase listed Observational

Mobilization and Outcomes After Venous Closure

NCT07246902
View directory record Official record
Conditions
Venous Vascular Closure, Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure Device
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 2:33 PM EDT
Active, not recruiting Not applicable Interventional

Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

NCT03540745
View directory record Official record
Conditions
Depression, Anxiety, Insomnia, Substance Abuse
Interventions
TES Treatment, TES-SHAM Treatment
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Belle Mead, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 22, 2026, 2:33 PM EDT
Recruiting Phase 2 Interventional

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

NCT05832086
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet
Behavioral
Lead sponsor
Stephen Freedland
Other
Eligibility
Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 2:33 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus

NCT04192773
View directory record Official record
Conditions
Tinnitus
Interventions
IV Lidocaine
Drug
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 2:33 PM EDT
Completed No phase listed Observational

Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques

NCT02210429
View directory record Official record
Conditions
Acute Pain, Pain, Postoperative
Interventions
Elbow Fracture Fixation
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 2:33 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 22, 2026, 2:33 PM EDT
Terminated Not applicable Interventional Results available

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

NCT00328094
View directory record Official record
Conditions
Peripheral Vascular Disease, Abdominal Aortic Aneurysm
Interventions
continuous intravenous insulin infusion
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00707031
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 22, 2026, 2:33 PM EDT
Recruiting Phase 2 Interventional

Eating Disorder Chatbot Optimization

NCT07218302
View directory record Official record
Conditions
Eating Disorders
Interventions
Digital Chatbot Program
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 2:33 PM EDT